Protagonist Therapeutics (PTGX) Tops Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts PTGX Hot Sheet
Join SI Premium – FREE
Protagonist Therapeutics (NASDAQ: PTGX) reported Q3 EPS of ($0.54), $0.04 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $4.68 million versus the consensus estimate of $1 million.
For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Reading (RDI) Tops Q2 EPS by 4c
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
